Skip to content

Ligand Pharmaceuticals acquires xCella Biosciences and Taurus Biosciences

September 10, 2020

Ligand Pharmaceuticals (NASDAQ:LGND) acquired two privately held companies that strengthen and complement its OmniAb® technology platform.

xCella Biosciences was acquired for $7M in cash plus potential earnouts, and Taurus Biosciences for $5M in cash plus non-transferable contingent value rights.

In addition, Ligand will invest $2.5M in a new company, Minotaur Therapeutics, which will be led by Taurus Biosciences’ founder, in exchange for royalties on products from future programs.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: